51. 全身性強皮症 Scleroderma Clinical trials / Disease details

臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

215 trials found

diseases per page:

Showing 1 to 10 of 215 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04986605 (ClinicalTrials.gov)	December 1, 2023	1/6/2021	Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis	The Effectiveness of ECP in Diffuse Cutaneous Systemic Sclerosis	Diffuse Cutaneous Systemic Sclerosis	Device: Extracorporeal Photopheresis (ECP);Drug: UVADEX	Lawson Health Research Institute	Mallinckrodt	Not yet recruiting	18 Years	N/A	All	15	Phase 2	Canada
2	NCT05149768 (ClinicalTrials.gov)	September 1, 2023	24/11/2021	Open Label Extension Study of Brentuximab Vedotin in Early dcSSc	An Open Label Extension Study of Brentuximab Vedotin Treatment in Active Diffuse Cutaneous Systemic ...	Diffuse Cutaneous Systemic Sclerosis	Drug: Brentuximab vedotin	Lawson Health Research Institute	Seagen Inc.	Not yet recruiting	18 Years	N/A	All	10	Phase 2	NULL
3	NCT05029336 (ClinicalTrials.gov)	September 2023	24/8/2021	Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases	Autologous Hematopoietic Stem Cell Transplant for Children and Young Adults With Life Threatening Au ...	Systemic Lupus Erythematosus;Systemic Sclerosis	Biological: Depletion of CD3/CD19 in an autologous stem cell transplant	Stephan Grupp MD PhD	NULL	Recruiting	8 Years	25 Years	All	20	Phase 2	United States
4	NCT04948554 (ClinicalTrials.gov)	March 10, 2023	4/6/2021	A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial ...	A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate t ...	Systemic Sclerosis With and Without Interstitial Lung Disease	Biological: MK-2225;Biological: Placebo	Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & C ...	NULL	Recruiting	18 Years	N/A	All	48	Phase 1	United States;Canada
5	NCT04789850 (ClinicalTrials.gov)	February 2, 2023	10/2/2021	Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis	Safety and Efficacy of Itacitinib in Adults With Systemic Sclerosis: a Phase II, Randomized, Control ...	Systemic Sclerosis	Drug: Itacitinib;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	NULL	Recruiting	18 Years	N/A	All	74	Phase 2	France
6	NCT05462522 (ClinicalTrials.gov)	January 16, 2023	14/7/2022	A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With ...	A Phase Ib, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Safety, ...	Systemic Sclerosis	Drug: RO7303509;Drug: Placebo	Genentech, Inc.	NULL	Recruiting	18 Years	75 Years	All	100	Phase 1	United States;Belgium;France;Israel;Poland;Puerto Rico;Spain
7	NCT04356287 (ClinicalTrials.gov)	January 5, 2023	15/4/2020	Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis	Phase I/II Randomized Controlled Trial of Umbilical Cord-derived mesenChymAl stRomal cElls in System ...	Sclerosis, Systemic;Mesenchymal Stem Cells	Biological: UCMSC;Other: Placebo	Marie Hudson, MD	Medical University of South Carolina;McGill University Health Centre/Research Institute of the McGil ...	Recruiting	18 Years	N/A	All	18	Phase 1/Phase 2	Canada
8	NCT03800017 (ClinicalTrials.gov)	January 1, 2023	21/11/2018	Skeletal Muscle Function in Interstitial Lung Disease	Investigating the Role of Skeletal Muscle Dysfunction on Dyspnea and Exercise Intolerance in Interst ...	Interstitial Lung Disease;Idiopathic Pulmonary Fibrosis;Hypersensitivity Pneumonitis;Scleroderma;Non ...	Biological: Hyperoxia	University of British Columbia	NULL	Not yet recruiting	40 Years	80 Years	All	40	N/A	NULL
9	NCT05559580 (ClinicalTrials.gov)	November 24, 2022	26/9/2022	A Study in People With Systemic Sclerosis to Test Whether BI 685509 Has an Effect on Lung Function a ...	A Phase II, Randomised, Placebo-controlled, Double-blind, Parallel Group, Efficacy and Safety Study ...	Scleroderma, Systemic	Drug: BI 685509;Drug: Placebo	Boehringer Ingelheim	NULL	Recruiting	18 Years	N/A	All	200	Phase 2	Australia;Austria;Belgium;Canada;China;Czechia;Finland;France;Greece;Italy;Japan;Korea, Republic of; ...
10	NCT05298358 (ClinicalTrials.gov)	November 18, 2022	7/3/2022	RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis	A Phase I Study of Reduced Intensity Conditioning Allogeneic Bone Marrow Transplant With Post-transp ...	Systemic Sclerosis	Biological: RIC alloBMT w PTCy in refractory SSc	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	NULL	Recruiting	18 Years	65 Years	All	30	Phase 1	United States

First Previous1 2 3 4 5…22Next Last